Sign in
CompletedNo phase

Alwide Plus China Post-market Clinical Investigation

Key facts

Who runs it
Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Where
China4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
75 people enrolled
Started
3 Jan 2025
Ended
4 Nov 2025
Type of study
Observational
Record updated
26 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Age≥18 years old
  • Severe aortic stenosis verified by echocardiogram: mean transvalvular gradient≥40mmHg (1mmHg=0.133kPa), or peak aortic jet velocity≥4m/s, or aortic valve area (AVA) ≤ 1.0cm2 (or AVA index≤ 0.6cm2/m2)
  • Patients, who can understand the clinical investigation purpose, voluntary agree and sign the informed consent form, and willing to comply with relevant trial assessments and clinical follow up

Who cannot take part

  • Acute myocardial infarction (MI) occurred in the last 30 days before the treatment;
  • Unable to receive anticoagulation or antiplatelet therapy;
  • Patients who participated in other clinic trials of drugs or medical device before being enrolled for which the primary endpoint follow up duration has not been reached;
  • Allergy to nitinol or sensitive contrast media;
  • Active bacterial endocarditis or other active infection may affect the procedure;
  • vulnerable individuals who are unable to give informed consent/ unable to fully understand all aspects of the investigation or Severe incapacitating Alzheimer's disease;
  • Serious left ventricular dysfunction with left ventricular ejection fraction (LVEF) <20%
  • Aortic valve anatomy or lesion unsuitable or not necessary for balloon pre-dilation during the TAVR procedure
  • TAVR procedure in trans-apical access
  • Pre-implanted mechanical or bioprosthetic valve at the aortic valve position
  • LVOT obstruction
  • Echocardiographic evidence of intracardiac mass, thrombus or neoplasm;
  • Aortic valve anatomy , lesion, or other situation unsuitable for the prosthesis valve implantation as assessed by the investigator team;
  • Life expectancy > 12 months;
  • Investigators determined that patients have poor compliance and can't complete the study as required

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a prospective, single-arm, multi-center, post-market registry study conducted in China. The purpose is to evaluate the safety and effectiveness of the AlwideTM Plus balloon catheter for pre-dilatation of the aortic valve during TAVR in the real-world setting.

The group in the trial

  • Alwide Plus

    Paitents perfomed TAVR and have Alwlide Plus Balloon Catheter pre-dilaton or post-dilation

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multicenter, Post-market Clinical Investigation to Evaluate the Pre-dilation Safety and Effectiveness of Alwide Plus Balloon Catheter of MicroPort CardioFlow in Transcatheter Aortic Valve Replacement
Record updated
26 December 2025